Scholarlink

Background <p>Ischemic wounds pose a challenge to conventional treatments due to insufficient blood and oxygen supply, exacerbating patient distress and often rendering traditional treatments ineffective. Thus, improving the healing rate of ischemic wounds remains a significant challenge requiring further research and solutions.</p> Methods <p>HaCaT and HUVEC were exposed to Sal-B under hypoxic conditions in vitro to assess proliferation, migration, and angiogenesis. Further, the mechanisms of action were investigated. In vivo, a mouse ischemic wound model was treated with Sal-B topically, with group comparisons including control (PBS), VEGF (100&#xa0;ng/ml), and Sal-B (50&#xa0;μmol/L, 100 μmol/L) utilizing immunofluorescence and H&amp;E staining.</p> Results <p>Salvianolic acid B notably increased HaCaT and HUVEC proliferation, migration, and tube formation in vitro and improved ischemic wound healing rates in vivo. It modulated crucial factors such as HIF-1α, TGF-β, MMP2, and bFGF.</p> Conclusion <p>This study indicates that salvianolic acid B promotes the healing of ischemic wounds under hypoxic conditions through multiple mechanisms. Specifically, salvianolic acid B effectively reduces the expression of HIF-1α while increasing the levels of TGF-β and bFGF, which are crucial for cell proliferation and new blood vessel formation during the wound healing process. Additionally, salvianolic acid B significantly enhances the proliferation, migration, and tube formation of HaCaT and HUVEC, accelerating wound closure, validating its potential for clinical application and highlighting new treatment strategies.</p> No Level Assigned <p>This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors &#xa0;<a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigating the Therapeutic Potential of Salvianolic Acid B in Ischemic Wound Healing: In Vivo and In Vitro Study

  • 期刊论文

  • 发表日期：

    2025年4月14日

查看全文
  • YiTung Tsai,
  • JiaMing Sun,
  • YuXin Liu,
  • ChioHou Chong,
  • DanNing Zheng,
  • Yifan Zhang,
  • Li Yu

摘要

Background

Ischemic wounds pose a challenge to conventional treatments due to insufficient blood and oxygen supply, exacerbating patient distress and often rendering traditional treatments ineffective. Thus, improving the healing rate of ischemic wounds remains a significant challenge requiring further research and solutions.

Methods

HaCaT and HUVEC were exposed to Sal-B under hypoxic conditions in vitro to assess proliferation, migration, and angiogenesis. Further, the mechanisms of action were investigated. In vivo, a mouse ischemic wound model was treated with Sal-B topically, with group comparisons including control (PBS), VEGF (100 ng/ml), and Sal-B (50 μmol/L, 100 μmol/L) utilizing immunofluorescence and H&E staining.

Results

Salvianolic acid B notably increased HaCaT and HUVEC proliferation, migration, and tube formation in vitro and improved ischemic wound healing rates in vivo. It modulated crucial factors such as HIF-1α, TGF-β, MMP2, and bFGF.

Conclusion

This study indicates that salvianolic acid B promotes the healing of ischemic wounds under hypoxic conditions through multiple mechanisms. Specifically, salvianolic acid B effectively reduces the expression of HIF-1α while increasing the levels of TGF-β and bFGF, which are crucial for cell proliferation and new blood vessel formation during the wound healing process. Additionally, salvianolic acid B significantly enhances the proliferation, migration, and tube formation of HaCaT and HUVEC, accelerating wound closure, validating its potential for clinical application and highlighting new treatment strategies.

No Level Assigned

This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors  www.springer.com/00266.

Graphical Abstract